Sakurai, Masatoshi



School of Medicine, Department of Internal Medicine (Hematology) (Shinanomachi)


Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)


Research Areas 【 Display / hide

  • Hematology

Research Keywords 【 Display / hide

  • hematological malignancies

  • hematopoietic stem cell

  • hematopoietic stem cell transplantation


Papers 【 Display / hide

  • Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

    Sakurai M., Kikuchi T., Karigane D., Kasahara H., Matsuki E., Hashida R., Yamane Y., Abe R., Koda Y., Toyama T., Kato J., Shimizu T., Yokoyama Y., Suzuki S., Nakamura T., Okamoto S., Mori T.

    International Journal of Hematology (International Journal of Hematology)  109 ( 3 ) 292 - 298 2019.03

    ISSN  09255710

     View Summary

    © 2019, Japanese Society of Hematology. Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. The mean estimated glomerular filtration rate (eGFR) was significantly decreased over 5 years (77 ± 17 to 62 ± 14 ml/min/1.73m², P < 0.001). Higher age and lower eGFR value at initiation of imatinib were significantly associated with development of renal dysfunction by multivariate analyses. Mean hemoglobin levels also significantly decreased over the 5-year period (12.9 ± 1.7 to 12.4 ± 1.3 g/dl, P < 0.01). The rate of decrease in eGFR correlated significantly with hemoglobin levels (correlation coefficient = − 0.249, P < 0.05). Serum erythropoietin (EPO) levels did not increase in 16 patients with both renal dysfunction and anemia (median, 31.9 mIU/ml). In patients who participated in a clinical trial of imatinib discontinuation, mean eGFR (50.0 ± 6.5 to 56.0 ± 10.2 ml/min/1.73m², P < 0.05) and hemoglobin levels (12.0 ± 1.7 to 14.0 ± 1.6 g/dl, P < 0.01) improved significantly at 1 year after discontinuation. These findings suggest that long-term imatinib results in a partially reversible continuous decline in renal function and decreased hemoglobin levels.

  • Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma

    Sakurai M., Karigane D., Kasahara H., Tanigawa T., Ishida A., Murakami H., Kikuchi M., Kohashi S.

    Annals of Hematology (Annals of Hematology)  98 ( 3 ) 669 - 678 2019.03

    ISSN  09395555

     View Summary

    © 2018, Springer-Verlag GmbH Germany, part of Springer Nature. The proportion of elderly patients with diffuse large B cell lymphoma (DLBCL) appears to be increasing, with outcomes varying widely because of the patients’ heterogeneity. Geriatric assessment is used to predict prognosis in elderly patients with DLBCL, but the utility of two simple screening tools for patients with DLBCL, the Flemish version of the Triage Risk Screening Tool (fTRST) and G8, has remained to be elucidated. We retrospectively assessed patients using fTRST and G8, and evaluated the impacts of the scores on survival outcomes in older patients with newly diagnosed DLBCL. A total of 59 patients aged 65 years or older and who were diagnosed with DLBCL were included. The median age was 77 years (range, 65–91 years), and the initial treatments were R-CHOP (63%) and R-THPCOP (31%). The estimated 2-year overall survival (OS) rate was significantly lower in patients with abnormal fTRST scores (≥ 2; N = 17) than in those with normal fTRST scores (< 2; N = 42): (50.5% (95% CI, 22.7–73.0%) vs. 82.2% (95% CI, 63.8–91.8%), P = 0.007). The estimated 2-year OS rate was significantly lower also in patients with abnormal G8 scores (≤ 14; N = 38) than in those with normal G8 scores (> 14; N = 21): (66.1% (95% CI, 46.7–79.5%) vs. 86.8% (95% CI, 55.7–96.7%), P = 0.03, respectively). These associations were independently significant after adjusting for other significant factors by multivariate analysis. These results suggest that the easy-to-use geriatric screening tools, fTRST and G8, have strong prognostic value for OS in older patients with DLBCL.

  • Invasive hepatic mucormycosis: A case report and review of the literature

    Karigane D., Kikuchi T., Sakurai M., Kato J., Yamane Y., Hashida R., Abe R., Hatano M., Hasegawa N., Wakayama M., Shibuya K., Okamoto S., Mori T.

    Journal of Infection and Chemotherapy (Journal of Infection and Chemotherapy)  25 ( 1 ) 50 - 53 2019.01

    ISSN  1341321X

     View Summary

    © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases Mucormycosis generally develops under immunocompromised conditions, including hematological malignancies and solid organ or hematopoietic stem cell transplantation. Although mucormycosis usually affects the lungs and paranasal sinuses, sporadic cases of invasive mucormycosis of the liver have been reported. We hereby report a patient with myelofibrosis who developed hepatic mucormycosis diagnosed by post-mortem examination. An extensive literature review identified 13 reported cases of hepatic mucormycosis, including ours, without lung involvement. Most of the underlying diseases or conditions were hematological malignancies and solid organ transplantation. Three cases had splenic lesions and four had gastrointestinal lesions, suggesting the possibility of translocation to the liver and/or spleen from the gastrointestinal tracts. Hepatic mucormycosis should be recognized as one of the presentations of invasive mucormycosis, especially when hepatic nodules are found in immunocompromised patients such as those with hematological malignancy or recipients of solid organ transplantation.

  • Successful Steroid Therapy for Lipoid Pneumonia Developing After Allogeneic Hematopoietic Stem Cell Transplant: A Case Report

    Sakurai M., Kato J., Toyama T., Hashida R., Yamane Y., Abe R., Koda Y., Kohashi S., Kikuchi T., Hayashi Y., Nukaga S., Ueda S., Fukunaga K., Okamoto S., Mori T.

    Transplantation Proceedings (Transplantation Proceedings)  50 ( 10 ) 4096 - 4098 2018.12

    ISSN  00411345

     View Summary

    © 2018 Elsevier Inc. Lipoid pneumonia is an uncommon noninfectious inflammatory lung disease characterized by lipid deposition in the alveoli, and its etiology and treatment have not been elucidated. We report the case of a 32-year-old woman who developed lipoid pneumonia 9 months after allogeneic hematopoietic stem cell transplant for chronic myelogenous leukemia in lymphoid blast crisis. She complained of progressive cough and dyspnea shortly after discontinuation of immunosuppressive therapy given for graft-vs-host disease. Computed tomography demonstrated diffuse ground-glass opacities in the lungs, and pulmonary function test revealed restrictive impairment. Bronchoalveolar lavage fluid showed milky appearance, and transbronchial lung biopsy specimen revealed foamy macrophages infiltrating the alveoli. Based on these findings, she was diagnosed as having lipoid pneumonia. Prednisolone (1 mg/kg/d) promptly improved the symptoms, pulmonary shadows, and pulmonary function. The findings and clinical course of this case suggest that lipoid pneumonia should be recognized as one of the pulmonary complications of allogeneic hematopoietic stem cell transplantation.

  • Very Late Relapse of Acute Promyelocytic Leukemia 17 Years after Continuous Remission

    Sakurai M., Watanuki S., Kato J., Hashida R., Yamane Y., Karigane D., Mitsuhashi T., Murata M., Ueno H., Nakazato T., Okamoto S., Mori T.

    Internal medicine (Tokyo, Japan) (Internal medicine (Tokyo, Japan))  57 ( 22 ) 3299 - 3302 2018.11

     View Summary

    The prognosis of acute promyelocytic leukemia (APL) has been improved by the combination of all-trans retinoic acid (ATRA) with chemotherapy. Nonetheless, relapse occurs in a certain proportion of patients, mostly within three to four years after treatment. We herein report a patient treated with ATRA and chemotherapy achieving remission who relapsed approximately 17 years after the treatment. A literature review identified 5 additional reported cases of APL relapse after more than 10 years. None of them presented with generally established risk factors for relapse, such as a high leukocyte count. The potential for late relapse of APL occurring more than 10 years after treatment should be recognized.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Presentations 【 Display / hide

  • Impaired hematopoietic differentiation of iPSCs derived from a patient with FPD/AML.


    第17回造血器腫瘍研究会 (宮崎) , 2013, Oral Presentation(general)

  • 大量 melphalan 療法に伴う嘔気・嘔吐に対する aprepitant の有効性の検討。

    櫻井 政寿、森 毅彦、加藤 淳、山根 明子、小橋 澄子、清水 隆之、岡本 真一郎

    第35回日本造血細胞移植学会 (金沢) , 2013, Poster (general)

  • 若年者慢性骨髄性白血病患者におけるチロシンキナーゼ阻害薬の治療成績の検討


    第75回日本血液学会学術集会 (大阪) , 2013, Oral Presentation(general)

  • 国際PNHレジストリにおける日本人患者の特徴


    第75回日本血液学会学術集会 (大阪) , 2013

  • 家族性血小板異常症(FPD/AML)における血小板機能異常


    第75回日本血液学会学術集会 (大阪) , 2013, Oral Presentation(general)

display all >>